Since its discovery in England and France in 1986, vancomycin-resistant Enterococcus has
increasingly become a major nosocomial pathogen worldwide. Enterococci are prolific …

Introduction: Management of antimicrobial resistance in multi-drug-resistant-Klebsiella
pneumoniae (MDR-KP) is a major challenge for clinicians. The optimal treatment option for …

Infections in critically ill patients are associated with persistently poor clinical outcomes.
These patients have severely altered and variable antibiotic pharmacokinetics and are …

Objective: To discuss the altered pharmacokinetic properties of selected antibiotics in
critically ill patients and to develop basic dose adjustment principles for this patient …

Bacteria producing Klebsiella pneumoniae carbapenemases (KPCs) are rapidly emerging
as a cause of multidrug-resistant infections worldwide. Bacterial isolates harbouring these …

Multidrug-resistant (MDR) Klebsiella pneumoniae represents an increasing threat to human
health, causing difficult-to-treat infections with a high mortality rate. Since colistin is one of …

Background. On the basis of noninferiority trials, tigecycline received Food and Drug
Administration (FDA) approval in 2005. In 2010, the FDA warned in a safety communication …

Tetracyclines constitute a unique class of antibiotic agents, widely prescribed for both
community and hospital infections due to their broad spectrum of activity. Acting by …

Acinetobacter spp. are non-fermentative, strictly aerobic, Gram-negative microorganisms
with a confusing taxonomic history. The Acinetobacter baumannii–Acinetobacter …

Introduction: For the past three decades, carbapenems played a central role in our antibiotic
armamentarium, trusted to effectively treat infections caused by drug-resistant bacteria. The …